Tofersen
(Redirected from Qalsody)
Tofersen[edit | edit source]
Tofersen is an investigational antisense oligonucleotide designed to treat amyotrophic lateral sclerosis (ALS) associated with mutations in the superoxide dismutase 1 (SOD1) gene. It is a synthetic molecule that targets the mRNA of the SOD1 gene, aiming to reduce the production of the mutant SOD1 protein, which is implicated in the pathogenesis of ALS.
Mechanism of Action[edit | edit source]
Tofersen works by binding to the mRNA of the SOD1 gene, which is responsible for encoding the SOD1 protein. By binding to this mRNA, Tofersen promotes its degradation through the recruitment of RNase H, an enzyme that cleaves the RNA strand of RNA-DNA hybrids. This process reduces the levels of SOD1 protein, particularly the mutant forms that are toxic to motor neurons.
Clinical Development[edit | edit source]
Tofersen is currently undergoing clinical trials to evaluate its safety and efficacy in patients with SOD1-ALS. The trials are designed to assess the drug's ability to slow the progression of ALS symptoms and improve motor function. Initial studies have shown promise, with some patients experiencing stabilization of their condition.
Administration[edit | edit source]
Tofersen is administered via intrathecal injection, which involves delivering the drug directly into the cerebrospinal fluid (CSF) surrounding the spinal cord. This method of administration is chosen to ensure that the drug reaches the central nervous system, where it can exert its effects on motor neurons.
Potential Side Effects[edit | edit source]
As with any investigational drug, Tofersen may have side effects. Commonly reported side effects include headache, back pain, and procedural pain associated with the intrathecal injection. More serious side effects are being monitored in clinical trials to ensure patient safety.
Future Directions[edit | edit source]
Research is ongoing to determine the long-term efficacy and safety of Tofersen in treating SOD1-ALS. Additionally, studies are being conducted to explore the potential of antisense oligonucleotides in treating other forms of ALS and neurodegenerative diseases.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju, Prab R. Tumpati, MD
